Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRX NASDAQ:IMMP NASDAQ:PMVP NASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.37-2.9%$2.84$2.15▼$5.27$15.16M1.53107,899 shs51,218 shsIMMPPrima BioMed$0.36+0.7%$0.45$0.29▼$3.53$53.25M2.21972,047 shs388,612 shsPMVPPMV Pharmaceuticals$1.11+1.8%$1.30$0.96▼$1.88$58.13M1.36290,074 shs120,524 shsTILInstil Bio$7.92-0.1%$8.18$5.67▼$36.85$53.78M1.9124,945 shs12,411 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx+5.79%+3.27%+11.58%+31.94%-36.21%IMMPPrima BioMed+1.57%-7.03%-23.16%-24.73%-80.47%PMVPPMV Pharmaceuticals+2.83%-8.40%-23.24%-30.13%-3.54%TILInstil Bio-0.63%-2.58%-2.10%-4.00%-78.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.37-2.9%$2.84$2.15▼$5.27$15.16M1.53107,899 shs51,218 shsIMMPPrima BioMed$0.36+0.7%$0.45$0.29▼$3.53$53.25M2.21972,047 shs388,612 shsPMVPPMV Pharmaceuticals$1.11+1.8%$1.30$0.96▼$1.88$58.13M1.36290,074 shs120,524 shsTILInstil Bio$7.92-0.1%$8.18$5.67▼$36.85$53.78M1.9124,945 shs12,411 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx+5.79%+3.27%+11.58%+31.94%-36.21%IMMPPrima BioMed+1.57%-7.03%-23.16%-24.73%-80.47%PMVPPMV Pharmaceuticals+2.83%-8.40%-23.24%-30.13%-3.54%TILInstil Bio-0.63%-2.58%-2.10%-4.00%-78.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLRXBioLineRx 2.00HoldN/AN/AIMMPPrima BioMed 1.75Reduce$5.501,412.24% UpsidePMVPPMV Pharmaceuticals 2.67Moderate Buy$5.00350.45% UpsideTILInstil Bio 1.67Reduce$66.00733.33% UpsideCurrent Analyst Ratings BreakdownLatest BLRX, PMVP, TIL, and IMMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026PMVPPMV Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$6.00 ➝ $5.004/29/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026BLRXBioLineRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026PMVPPMV Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/27/2026TILInstil Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/13/2026IMMPPrima BioMed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold3/13/2026IMMPPrima BioMed Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$7.00 ➝ $1.003/13/2026IMMPPrima BioMed Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$1.18M12.48N/AN/A$5.36 per share0.63IMMPPrima BioMed$6.69M8.01N/AN/A$0.63 per share0.58PMVPPMV PharmaceuticalsN/AN/AN/AN/A$1.97 per shareN/ATILInstil BioN/AN/AN/AN/A$16.79 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$1.17M-$1.92N/AN/AN/A-563.70%-37.73%-19.42%8/13/2026 (Estimated)IMMPPrima BioMed-$39.78MN/AN/AN/AN/AN/AN/AN/AN/APMVPPMV Pharmaceuticals-$77.74M-$1.49N/AN/AN/AN/A-68.98%-62.70%8/6/2026 (Estimated)TILInstil Bio-$71.37M-$7.08N/AN/AN/AN/A-39.76%-22.38%8/12/2026 (Estimated)Latest BLRX, PMVP, TIL, and IMMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q1 2026BLRXBioLineRx-$1.04-$0.36+$0.68-$0.36$0.34 million$0.48 million5/15/2026Q1 2026TILInstil Bio-$0.62-$0.62N/A-$0.62N/AN/A5/12/2026Q1 2026PMVPPMV Pharmaceuticals-$0.41-$0.34+$0.07-$0.34N/AN/A3/27/2026Q4 2025TILInstil Bio-$2.31-$1.21+$1.10-$1.21$1.90 millionN/A3/24/2026Q4 2025BLRXBioLineRx-$0.50-$0.34+$0.16N/A$0.49 million$0.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx0.161.581.43IMMPPrima BioMedN/A2.97N/APMVPPMV PharmaceuticalsN/A11.1411.14TILInstil Bio0.7739.8739.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%IMMPPrima BioMed2.32%PMVPPMV Pharmaceuticals90.20%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%IMMPPrima BioMed3.07%PMVPPMV Pharmaceuticals7.57%TILInstil Bio47.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx404.37 million4.32 millionOptionableIMMPPrima BioMed2,021147.37 million142.85 millionOptionablePMVPPMV Pharmaceuticals5053.33 million49.30 millionOptionableTILInstil Bio4106.78 million3.59 millionNo DataBLRX, PMVP, TIL, and IMMP HeadlinesRecent News About These CompaniesInstil Bio Shareholders Back Directors and Auditor at MeetingJune 11 at 6:31 PM | tipranks.comInstil Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comInstil Bio (TIL) Price Target Increased by 24.53% to 67.32April 9, 2026 | msn.comInstil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILFebruary 12, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILFebruary 3, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 29, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio,January 27, 2026 | bakersfield.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 22, 2026 | prnewswire.comTIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & KorsinskyJanuary 20, 2026 | newsfilecorp.comNINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 20, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 15, 2026 | prnewswire.comInstil Bio (TIL) Price Target Decreased by 45.17% to 53.55January 14, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 13, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 8, 2026 | prnewswire.comHC Wainwright & Co. downgrades Instil Bio (TIL)January 8, 2026 | msn.comArrowhead showcases early obesity data; Instil bails on PD-1/VEGF drugJanuary 7, 2026 | biopharmadive.comBInstil Bio shares slide on discontinuation of lead clinical programsJanuary 6, 2026 | proactiveinvestors.comInstil Bio Pulls Plug On Lead Drug DevelopmentJanuary 6, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20263 Rare Earth Stocks That Win No Matter What China Does NextBy Bridget Bennett | May 24, 2026Is Everspin Technologies the Next AI Edge Breakout?By Thomas Hughes | May 18, 2026Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemBy Dan Schmidt | May 30, 2026Snowflake and the Snowballing Impact of its AI FlywheelBy Thomas Hughes | May 28, 2026BLRX, PMVP, TIL, and IMMP Company DescriptionsBioLineRx NASDAQ:BLRX$3.37 -0.10 (-2.88%) Closing price 04:00 PM EasternExtended Trading$3.39 +0.02 (+0.59%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Prima BioMed NASDAQ:IMMP$0.36 +0.00 (+0.66%) Closing price 04:00 PM EasternExtended Trading$0.36 0.00 (-0.47%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.PMV Pharmaceuticals NASDAQ:PMVP$1.11 +0.02 (+1.83%) Closing price 04:00 PM EasternExtended Trading$1.12 +0.01 (+0.63%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Instil Bio NASDAQ:TIL$7.92 -0.01 (-0.13%) Closing price 04:00 PM EasternExtended Trading$7.92 +0.00 (+0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
